A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-cell Malignancies
PNT2258 consists of a native, chemically unmodified, 24-base DNA oligonucleotide designed to target the regulatory region upstream of the BCL2 gene, delivered in a protective liposome. Derangement of BCL2-regulated control mechanisms is a defining characteristic of certain malignancies, and it was hypothesized that the oligonucleotide would promote anticancer activity via suppression of BCL2 transcription.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Wael Harb, Nehal J. Lakhani, Richard Messmann, Barbara Klencke, Ayad M. Al-Katib Source Type: research
More News: Cancer & Oncology | Chemistry | Genetics | Hematology | Leukemia | Lymphoma | Myeloma | Study